Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
ConditionOlfactory Neuroblastoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorHongmeng Yu
About this trial
The goal of this clinical trial is to learn about the induction chemotherapy efficacy in olfactory neuroblastoma. The main question it aims to answer is: wether olfactory neuroblastoma patients with different pathology subtypes apply to different induction chemotherapy schemes. Participants will be treated with different chemotherapy schemes, to evaluate the tumor remission rate and long term survival.
Eligibility criteria
Qualifiers
Patients with pathologically confirmed olfactory neuroblastoma;
Age ≥ 18 years old;
Dulguerov stage T2-T4;
Patients who signed the informed consent forms;
Disqualifiers
Patients with uncontrolled concurrent diseases that the researchers believe will interfere with treatment;
Any situation in which the patient may interfere with the compliance or safety during the study;
Severe neurological or mental illness, including dementia and seizures;
Uncontrolled active infection;
Trial design
Treatments tested in this trial
- Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Hongmeng Yu
Lead sponsor
Eye & ENT Hospital of Fudan University
Sponsor institution
Source ClinicalTrials.gov